Neurocrine Biosciences Inc. Insider Trading

NBIX

Last 12 months

Insiders sold $79.3M and bought nothing on the open market.

All of the selling was scheduled in advance under 10b5-1 plans. The last open-market buy by an executive or director was in Nov 2009.

Net open-market

−$79.3M

0 buys · 25 sales

Under a 10b5-1 plan

100%

of the value sold

Insiders who bought / sold

0 / 15

executives and directors

Last open-market buy

Nov 2009

Nov 5, 2009

Get an email when NBIX's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 30 – Nov 3	George J Morrow Director	Sold10b5-1 plan 12 parts	15,000	$155.73 average	$2.34M	59%	Form 4
Sep 14	David W. Boyer Chief Corp. Affairs Officer	Sold10b5-1 plan	826	$157.45	130K	8.7%	Form 4
Sep 14	Matt Abernethy Chief Financial Officer	Sold10b5-1 plan	2,311	$157.20	363K	5.1%	Form 4
Sep 9	Eric Benevich Chief Commercial Officer	Sold10b5-1 plan	2,154	$154.61	333K	3.2%	Form 4
Jul 28	Leslie V Norwalk Director	Sold10b5-1 plan	1,250	$182.01	228K	34%	Form 4
Jul 10	Ingrid Delaet Chief Regulatory Officer	Sold10b5-1 plan	4,367	$181.02	791K	21%	Form 4
Jul 9	Darin Lippoldt Chief Legal Officer	Sold10b5-1 plan	10,000	$179.60	$1.8M	15%	Form 4
Jul 7 – 9	Ingrid Delaet Chief Regulatory Officer	Sold10b5-1 plan 3 parts	14,571	$178.65 average	$2.6M	47%	Form 4
Jun 26 – 29	Darin Lippoldt Chief Legal Officer	Sold10b5-1 plan 3 parts	10,000	$170.15 average	$1.7M	15%	Form 4
Jun 5	Stephen A Sherwin Director	Sold10b5-1 plan 5 parts	25,000	$165.32 average	$4.13M	61%	Form 4
Jun 4	Leslie V Norwalk Director	Sold10b5-1 plan	1,250	$168.06	210K	31%	Form 4
Jun 2	Julie Cooke Chief Human Resources Officer	Sold10b5-1 plan 5 parts	36,937	$156.22 average	$5.77M	62%	Form 4
Jun 1	Jude Onyia Chief Scientific Officer	Sold10b5-1 plan	11,000	$160.25	$1.76M	30%	Form 4
May 29	Ingrid Delaet Chief Regulatory Officer	Sold10b5-1 plan	2,261	$156.71	354K	12%	Form 4
May 27	Jude Onyia Chief Scientific Officer	Sold10b5-1 plan	11,000	$155.53	$1.71M	30%	Form 4
May 26	David W. Boyer Chief Corp. Affairs Officer	Sold10b5-1 plan	3,888	$156.64	609K	33%	Form 4
May 19	Kevin Charles Gorman Director	Sold10b5-1 plan	245,088	$154.33	$37.8M	32%	Form 4
May 15	Richard F Pops Director	Sold10b5-1 plan	15,000	$157.65	$2.36M	30%	Form 4
May 12	Leslie V Norwalk Director	Sold10b5-1 plan	3,810	$155.01	591K	61%	Form 4
Jan 16	Kyle Gano Chief Executive Officer	Sold10b5-1 plan 2 parts	36,400	$132.70 average	$4.83M	21%	Form 4
Dec 15, 2025 – Dec 16, 2025	Leslie V Norwalk Director	Sold10b5-1 plan 2 parts	6,190	$152.78 average	946K	50%	Form 4
Dec 8, 2025	Darin Lippoldt Chief Legal Officer	Sold10b5-1 plan	4,376	$159.65	699K	9.2%	Form 4
Dec 3, 2025	Gary A Lyons Director	Sold10b5-1 plan	15,000	$152.61	$2.29M	11%	Form 4
Nov 25, 2025	George J Morrow Director	Sold10b5-1 plan	15,000	$143.37	$2.15M	68%	Form 4
Nov 5, 2025	William H Rastetter Director	Sold10b5-1 plan	18,000	$151.82	$2.73M	31%	Form 4
Nov 4, 2025	Kyle Gano Chief Executive Officer	Sold10b5-1 plan	300	$141.97	43K	0.2%	Form 4
Aug 7, 2025	Kevin Charles Gorman Director	Sold10b5-1 plan	106,322	$126.41	$13.4M	17%	Form 4
Jul 10, 2025	Ingrid Delaet Chief Regulatory Officer	Sold10b5-1 plan	457	$135.00	62K	8.8%	Form 4
Jul 9, 2025	Jude Onyia Chief Scientific Officer	Sold10b5-1 plan	59,819	$130.46	$7.8M	77%	Form 4
Jul 2, 2025	Jude Onyia Chief Scientific Officer	Sold10b5-1 plan	20,362	$130.13	$2.65M	53%	Form 4
May 27, 2025	Kevin Charles Gorman Director	Sold10b5-1 plan	9,613	$120.38	$1.16M	1.8%	Form 4
May 5, 2025	William H Rastetter Director	Sold10b5-1 plan	30,000	$110.20	$3.31M	44%	Form 4
Feb 13, 2025 – Feb 14, 2025	Eiry Roberts Chief Medical Officer	Sold10b5-1 plan 3 parts	2,218	$116.44 average	258K	5.9%	Form 4
Feb 13, 2025	Julie Cooke Chief Human Resources Officer	Sold10b5-1 plan 2 parts	1,551	$116.78 average	181K	7.1%	Form 4
Feb 13, 2025	Kevin Charles Gorman Director	Sold10b5-1 plan 2 parts	5,844	$116.68 average	682K	1.1%	Form 4
Feb 13, 2025	Stephen A Sherwin Director	Sold10b5-1 plan	13,831	$116.69	$1.61M	56%	Form 4
Feb 13, 2025	Jude Onyia Chief Scientific Officer	Sold10b5-1 plan 2 parts	2,879	$116.79 average	336K	14%	Form 4
Feb 13, 2025	Darin Lippoldt Chief Legal Officer	Sold10b5-1 plan 2 parts	2,184	$116.76 average	255K	4.8%	Form 4
Feb 13, 2025	Kyle Gano Chief Executive Officer	Sold10b5-1 plan 2 parts	2,558	$116.85 average	299K	1.8%	Form 4
Feb 13, 2025	Ingrid Delaet Chief Regulatory Officer	Sold10b5-1 plan 2 parts	1,471	$116.71 average	172K	24%	Form 4

Oct 30 – Nov 310b5-1 plan
George J Morrow
Director · sold 15,000 at avg $155.73
$2.34M
59% of stake
Sep 1410b5-1 plan
David W. Boyer
Chief Corp. Affairs Officer · sold 826 at $157.45
130K
8.7% of stake
Sep 1410b5-1 plan
Matt Abernethy
Chief Financial Officer · sold 2,311 at $157.20
363K
5.1% of stake
Sep 910b5-1 plan
Eric Benevich
Chief Commercial Officer · sold 2,154 at $154.61
333K
3.2% of stake
Jul 2810b5-1 plan
Leslie V Norwalk
Director · sold 1,250 at $182.01
228K
34% of stake
Jul 1010b5-1 plan
Ingrid Delaet
Chief Regulatory Officer · sold 4,367 at $181.02
791K
21% of stake
Jul 910b5-1 plan
Darin Lippoldt
Chief Legal Officer · sold 10,000 at $179.60
$1.8M
15% of stake
Jul 7 – 910b5-1 plan
Ingrid Delaet
Chief Regulatory Officer · sold 14,571 at avg $178.65
$2.6M
47% of stake
Jun 26 – 2910b5-1 plan
Darin Lippoldt
Chief Legal Officer · sold 10,000 at avg $170.15
$1.7M
15% of stake
Jun 510b5-1 plan
Stephen A Sherwin
Director · sold 25,000 at avg $165.32
$4.13M
61% of stake
Jun 410b5-1 plan
Leslie V Norwalk
Director · sold 1,250 at $168.06
210K
31% of stake
Jun 210b5-1 plan
Julie Cooke
Chief Human Resources Officer · sold 36,937 at avg $156.22
$5.77M
62% of stake
Jun 110b5-1 plan
Jude Onyia
Chief Scientific Officer · sold 11,000 at $160.25
$1.76M
30% of stake
May 2910b5-1 plan
Ingrid Delaet
Chief Regulatory Officer · sold 2,261 at $156.71
354K
12% of stake
May 2710b5-1 plan
Jude Onyia
Chief Scientific Officer · sold 11,000 at $155.53
$1.71M
30% of stake
May 2610b5-1 plan
David W. Boyer
Chief Corp. Affairs Officer · sold 3,888 at $156.64
609K
33% of stake
May 1910b5-1 plan
Kevin Charles Gorman
Director · sold 245,088 at $154.33
$37.8M
32% of stake
May 1510b5-1 plan
Richard F Pops
Director · sold 15,000 at $157.65
$2.36M
30% of stake
May 1210b5-1 plan
Leslie V Norwalk
Director · sold 3,810 at $155.01
591K
61% of stake
Jan 1610b5-1 plan
Kyle Gano
Chief Executive Officer · sold 36,400 at avg $132.70
$4.83M
21% of stake
Dec 15, 2025 – Dec 16, 202510b5-1 plan
Leslie V Norwalk
Director · sold 6,190 at avg $152.78
946K
50% of stake
Dec 8, 202510b5-1 plan
Darin Lippoldt
Chief Legal Officer · sold 4,376 at $159.65
699K
9.2% of stake
Dec 3, 202510b5-1 plan
Gary A Lyons
Director · sold 15,000 at $152.61
$2.29M
11% of stake
Nov 25, 202510b5-1 plan
George J Morrow
Director · sold 15,000 at $143.37
$2.15M
68% of stake
Nov 5, 202510b5-1 plan
William H Rastetter
Director · sold 18,000 at $151.82
$2.73M
31% of stake
Nov 4, 202510b5-1 plan
Kyle Gano
Chief Executive Officer · sold 300 at $141.97
43K
0.2% of stake
Aug 7, 202510b5-1 plan
Kevin Charles Gorman
Director · sold 106,322 at $126.41
$13.4M
17% of stake
Jul 10, 202510b5-1 plan
Ingrid Delaet
Chief Regulatory Officer · sold 457 at $135.00
62K
8.8% of stake
Jul 9, 202510b5-1 plan
Jude Onyia
Chief Scientific Officer · sold 59,819 at $130.46
$7.8M
77% of stake
Jul 2, 202510b5-1 plan
Jude Onyia
Chief Scientific Officer · sold 20,362 at $130.13
$2.65M
53% of stake
May 27, 202510b5-1 plan
Kevin Charles Gorman
Director · sold 9,613 at $120.38
$1.16M
1.8% of stake
May 5, 202510b5-1 plan
William H Rastetter
Director · sold 30,000 at $110.20
$3.31M
44% of stake
Feb 13, 2025 – Feb 14, 202510b5-1 plan
Eiry Roberts
Chief Medical Officer · sold 2,218 at avg $116.44
258K
5.9% of stake
Feb 13, 202510b5-1 plan
Julie Cooke
Chief Human Resources Officer · sold 1,551 at avg $116.78
181K
7.1% of stake
Feb 13, 202510b5-1 plan
Kevin Charles Gorman
Director · sold 5,844 at avg $116.68
682K
1.1% of stake
Feb 13, 202510b5-1 plan
Stephen A Sherwin
Director · sold 13,831 at $116.69
$1.61M
56% of stake
Feb 13, 202510b5-1 plan
Jude Onyia
Chief Scientific Officer · sold 2,879 at avg $116.79
336K
14% of stake
Feb 13, 202510b5-1 plan
Darin Lippoldt
Chief Legal Officer · sold 2,184 at avg $116.76
255K
4.8% of stake
Feb 13, 202510b5-1 plan
Kyle Gano
Chief Executive Officer · sold 2,558 at avg $116.85
299K
1.8% of stake
Feb 13, 202510b5-1 plan
Ingrid Delaet
Chief Regulatory Officer · sold 1,471 at avg $116.71
172K
24% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch NBIX, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with NBIX

CompareIntrinsic value

EXELExelixis Inc.

$72.75+0.61%97

MRNAModerna, Inc.

$258.31+13.08%20

HALOHalozyme Therapeutics Inc.

$130.34+1.34%66

TECHBio-Techne Corporation

$72.73+0.10%52

BCRXBioCryst Pharmaceuticals Inc.

$8.24-3.85%64

RGENRepligen Corporation

$178.20-0.04%35

TARSTarsus Pharmaceuticals Inc.

$69.07-4.91%55

ADMAAdma Biologics Inc.

$10.48-5.67%82

Held by ETFs

NBIX is in 217 US ETFs. The largest of them, with NBIX's weight in each:

Spot a number that looks wrong? Check it in NBIX's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing NBIX

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.